[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"post-covid-19-condition\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:post-covid-19-condition":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,44,107,135,165,196,226,249,283,306,327,347,368,394,414,436],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100645261","phase-1-taurine-supplementation-in-adolescents-with-post-covid-condition-100645261",false,"NCT07682402","Taurine Supplementation in Adolescents With Post-COVID Condition","An Open-Label Study of Taurine Supplementation in Adolescents With Post-COVID Condition: Quantifying Taurine Plasma Levels and Evaluating Clinical and Biological Outcomes","TaurineLCPeds","Inclusion Criteria:\n\n1. Subjects must be between 10 and 17 years of age at the time of study enrollment\n2. Positive COVID-19 test by nasopharyngeal swab RT-PCR test, antibody or antigen tests at least 3 months prior to trial; OR Presumed COVID-19 assessed by the site investigator (no positive COVID-19 test) with acute illness after October 15, 2019, and at least 3 months prior to trial enrollment.\n3. If participants have treatable symptoms, they should have had a stable regimen of treatment prior to entering the study (i.e. started treatment for at least 4 weeks).\n4. Lingering COVID-19 symptoms beyond 3 months from onset of acute COVID and symptoms have lasted at least 2 months. The onset of COVID is considered the earliest of two dates: the date of positive testing or the date of first symptoms.\n5. Lingering symptoms from COVID-19 present at the time of trial enrollment.\n6. Individuals of childbearing potential (as assessed by the overseeing Investigator) who are sexually active must agree to practice true abstinence or use at least one highly effective method of contraception while on study treatment. Highly effective methods of contraception must be discussed and approved by the overseeing Investigator.\n7. Medication(s) only available through a prescription for the purposes of treating fatigue or cognitive function have been discontinued for four weeks prior to randomization.\n8. Participants must be able to assent to their participation in the study and be both willing and able to comply with study requirements.\n9. Parents\u002Fcaregivers\u002Fguardians must be able to provide informed consent for participation.\n10. Participants must agree to avoid taking supplemental taurine (e.g. from over-the-counter preparations, energy drinks, etc.)\n\nExclusion Criteria:\n\n1. Patients who had mechanical ventilation or extracorporeal membrane oxygen (ECMO) for COVID-19.\n2. Current end-organ failure, organ transplantation, or current hospitalization in an acute care hospital.\n3. Contraindications to the study intervention.\n4. Currently already on the study intervention (Participants would be eligible if they stopped taking Taurine for a minimum of 4 weeks prior to enrollment).\n5. Co-enrolment in another interventional trial (co-enrolment in an observational study is permitted).\n6. Currently pregnant or breastfeeding.\n7. The participant is currently enrolled in another research trial to treat neurocognitive symptoms in LC.","ALL","10 Years","17 Years",{"count":21,"type":22},30,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE1","PHASE2","The COVID-19 pandemic has swept across the globe, affecting millions of individuals with varying degrees of severity. While many individuals recover from the acute phase of the infection, a significant proportion continue to experience persistent and debilitating symptoms long after the initial SARS-CoV-2 infection. This condition, known as Long COVID (LC) or sometimes referred to as Post-COVID Condition (PCC) or post-acute sequelae of COVID-19 (PASC), has emerged as a complex multisystemic condition and challenging public health issue.\n\nContrary to initial perceptions, pediatric Long COVID is a significant health concern, with studies suggesting its prevalence ranges from 10% to 25% following infection. Research in the pediatric population has largely been limited to observational studies based on self-reported symptoms or large electronic healthcare datasets. The long-term outcomes and predictors of LC in children remain poorly described, highlighting an urgent need for further mechanistic research to characterize this complex condition. While acute COVID-19 symptoms are often milder in children relative to adults, some go on to develop a range of chronic physical, immunological, psychological, and neurological symptoms persisting for weeks to years after initial infection. The most commonly reported symptoms are similar to those seen in adults and include debilitating fatigue, respiratory distress, headaches, gastrointestinal symptoms, and neurocognitive impairment. Other frequently reported symptoms include muscle pain, sleep disturbances, olfactory and gustatory disturbances, exercise intolerance, and heart palpitations\u002Fcardiovascular symptoms. These symptoms can be new, or they may persist or fluctuate from the initial illness. Additionally, many children with LC experience psychological symptoms such as anxiety, depression, and mood disturbances, which are thought to be exacerbated by experiencing prolonged illness and subsequent lifestyle disruptions.\n\nCurrently, effective treatments for LC remain elusive, leaving patients to contend with persistent symptoms that significantly impair their quality of life. For children and adolescents, these issues can profoundly impact their daily activities, academic performance, and social interactions\u002Ffriendships. Symptoms like debilitating fatigue, cognitive impairment, and mood disturbances are especially disruptive by interfering with memory, energy levels, and overall development, often leading to school absenteeism, social withdrawal, and psychological distress. Therefore, it is imperative to explore novel therapeutic approaches that may alleviate the suffering of this patient population.",[29,30,31],"Long COVID","Post COVID-19 Condition","PASC Post Acute Sequelae of COVID 19","NOT_YET_RECRUITING","2026-06-26",{"date":35,"type":36},"2026-07-02","ACTUAL",{"date":38,"type":22},"2026-09-30",{"date":40,"type":22},"2028-12-31",{"name":42,"class":43},"University of Alberta","OTHER",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":4},"100611443","phase-4-outcomes-from-hyperbaric-oxygen-hbo2-treatment-for-emerging-indications-100611443","NCT07240649","Outcomes From Hyperbaric Oxygen (HBO2) Treatment for Emerging Indications","Emerging Indications for Hyperbaric Oxygen Treatment","Inclusion Criteria:\n\n* Patients referred for HBOT with an emerging indication\n\nExclusion Criteria:\n\n* Contraindication to hyperbaric oxygen treatment (untreated seizures, pneumothorax, significant pulmonary airspace pathology that might lead to pulmonary barotrauma, unmanageable confinement anxiety, chronic obstructive pulmonary disease with CO2 retention)\n* Pregnant persons",{"count":52,"type":22},100,[54],"PHASE4","This study will evaluate the effectiveness of hyperbaric oxygen therapy (HBOT) on treating emerging indications (i.e., conditions that have shown to potentially benefit from HBOT) using the Multicenter Registry for Hyperbaric Oxygen Treatment. The study team aims to collect ongoing data on how well HBOT treats these emerging indications, and to add these data to the growing HBO Registry. The research team hypothesizes that HBOT will result in improvements of the condition of the various emerging indications.",[57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97],"Post-COVID-19 Condition","Ulcerative Colitis","Crohn Disease","Calciphylaxis","Frostbite","Acute COVID-19","Pyoderma Gangrenosum","Pterygium","Hypospadias","Head Trauma","Pneumatosis Intestinalis","Ischemic Bowel","Raynaud Syndrome","Malignant Otitis Externa","Nonarteritic Anterior Ischemic Optic Neuropathy","Central Retinal Vein Occlusion","Femoral Head Necrosis","Invasive Fungal Infection","Chronic Anal Fissure","Vasculitic Ulcer","Graft-vs-Host Disease","Decubitus Ulcer","Greater Trochanteric Pain Syndrome","Rectovaginal Fistula","Pouchitis","Tinnitus","Clostridium Enterocolitis","Branch Retinal Artery Occlusion","Axonotmesis","Multiple Sclerosis","Inclusion Body Myositis","Epidermolysis Bullosa (EB)","Osteonecrosis","Ulcer Ischemic","Avascular Necrosis of Bone","Prosthesis Related Infections","Facial Filler Injections","Cystitis Chronic","Ligament Injury","Anastomosis, Leaking","Cartilage Injury","2026-05-01",{"date":100,"type":36},"2026-05-05",{"date":102,"type":22},"2026-08",{"date":104,"type":22},"2035-12",{"name":106,"class":43},"Jay C. Buckey Jr.",{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":115,"sex":17,"minAge":116,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":119,"phases":4,"briefSummary":120,"conditions":121,"keywords":122,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":134},"100603296","mitochondrial-function-in-peripheral-blood-mononuclear-cells-muscle-and-skin-of-long-covid-patients-100603296","NCT07134673","Mitochondrial Function in Peripheral Blood Mononuclear Cells, Muscle, and Skin of Long COVID Patients","Mitochondrial Oxygen Consumption and Substrate Utilisation In Vitro in Peripheral Blood Mononuclear Cells, and In Vivo on Muscle and Skin in Long COVID Patients and Convalescent Individuals: A Case-Control and Diagnostic Accuracy Study","MitoLoCo","Individuals with long COVID:\n\nInclusion criteria:\n\n* Long COVID diagnosis, based on the WHO definition;\n* Presence of long COVID symptoms for a minimum of 6 months.\n* History of confirmed or documented SARS-CoV-2 infection.\n* Adult (≥18 years of age).\n* Post-COVID-19 Functional Status Scale grade 2-4, while they had a grade 0 before the SARS-CoV-2 infection.\n\nExclusion criteria:\n\n* Pre-existing chronic diseases potentially affecting the functional status scale.\n* Treatment with metabolism altering drugs.\n* \\> 10 standard units of alcohol (10 grams of alcohol\u002Fglass) per week.\n* Unable to understand oral and written instructions in Dutch, French or English.\n* Allergies to medical adhesive bandages.\n* Porphyria and other skin conditions aggravated by sunlight.\n\nConvalescent individuals\n\nInclusion criteria:\n\n* History of confirmed or documented SARS-CoV-2 infection.\n* Complete recovery after the SARS-CoV-2 infection, no history of long COVID based on the WHO definition;\n* Post-COVID-19 Functional Status Scale \\[2\\] grade 0 both before the infection and currently.\n* Adult (≥18 years of age).\n\nExclusion criteria:\n\n* Pre-existing chronic non-communicable diseases (e.g. hypertension, chronic respiratory diseases, diabetes).\n* Treatment with metabolism altering drugs.\n* \\> 10 standard units of alcohol (10 grams of alcohol\u002Fglass) per week.\n* Unable to understand oral and written instructions in Dutch, French or English.\n* Allergies to medical adhesive bandages.\n* Porphyria and other skin conditions aggravated by sunlight.",true,"18 Years",{"count":118,"type":22},54,"OBSERVATIONAL","Mitochondria are structures inside cells that are responsible for producing energy from nutrients through a series of steps, using oxygen. To have an idea of how well the mitochondria can produce energy, we can measure how much oxygen they use. The goal of this study is to:\n\n1. To compare the oxygen use between people with long COVID and people who completely recovered after COVID-19, using three techniques that measure the oxygen use in blood cells, on the skin and in the muscle\n2. To test how similar these three techniques are in measuring the oxygen used in the three different tissues\n\nParticipants will:\n\n* Complete surveys,\n* Wear an activity tracker (7 days),\n* Undergo several non-invasive tests, and\n* Donate a blood sample The study will take place in UZ Brussel hospital and will take 2 study visits, approximately 7 days apart.",[29,57],[123],"mitochondrial dysfunction","RECRUITING","2026-04-21",{"date":127,"type":36},"2026-04-22",{"date":129,"type":36},"2026-01-21",{"date":131,"type":22},"2026-07",{"name":133,"class":43},"Universitair Ziekenhuis Brussel",1,{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":17,"minAge":116,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":23,"phases":145,"briefSummary":146,"conditions":147,"keywords":151,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":134},"100575018","phase-2-study-to-evaluate-the-efficacy-and-safety-of-plitidepsin-in-adults-with-post-covid-19-condition-pcc-100575018","NCT06766825","Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults With Post-COVID-19 Condition (PCC)","Phase II Proof-of-concept, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults With Post-COVID-19 Condition (PCC)","THALASSA","1. Male or female individuals 18 years old or older.\n2. Evidence of SARS-CoV-2 infection at least 90 days prior to study recruitment, defined by either (a) nasopharyngeal SARS-CoV-2 nucleic acid test \\[polymerase chain reaction (PCR) or transcription mediated amplification (TMA)\\], (b) validated Nasopharyngeal Lateral Flow Assay rapid antigen test (RAT), or (c) or positive serology against SARS-CoV-2 N protein regardless vaccination status.\n3. 3 or more symptoms of PCC affecting at least two organs, after 90 days from the onset of SARS-CoV2 infection and that last for at least 2 months and cannot be explained by an alternative diagnosis. Symptoms may be new onset following initial recovery from an acute COVID-19 episode or persist from the initial illness. Symptoms may also fluctuate or relapse over time.\n4. Unable to perform all usual duties\u002Factivities, defined as grades 3 or 4 in PCFS (Annex 3).\n5. Willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the study.\n6. Having understood the information provided and capable of providing informed consent\n\nEXCLUSION CRITERIA\n\n1. Last SARS-CoV-2 vaccine dose during the previous 30 days.\n2. Patients with active uncontrolled infections.\n3. Patients infected by SARS-CoV-2 virus in the last 90 days prior to the screening visit.\n4. Patients receiving treatment with strong cytochrome P450 3A4 (CYP3A4) inhibitors or inducers (Annex 1) throughout plitidepsin treatment period and until 24-h washout period.\n5. Pacients receiving chronic glucocorticoid therapy (high-dose corticosteroids \\[ie, 20 mg of prednisone daily or equivalent for ≥2 weeks)\n6. Any of the following cardiac conditions or risk factors:\n\n   * Cardiac infarction or cardiac surgery episode within the last six months 14\n   * History of known congenital QT prolongation;\n   * Known structural cardiomyopathy with abnormal left ventricular ejection fraction (LVEF) \\\u003C50%;\n   * Current clinical evidence of heart failure or acute cardiac ischaemia (New York Heart Association (NYHA) class III-IV).\n7. Hypersensitivity to the active ingredient or any of the excipients (mannitol, macrogolglycerol hydroxystearate, and ethanol) or contraindication to receive systemic glucocorticoids, antihistamine H1\u002FH2 receptor agents, or antiserotonine 5HT3 receptors drugs.\n8. Mast cell activation syndrome.\n9. Females who are pregnant (negative serum or urine pregnancy test required for all females of childbearing potential at screening) or breast-feeding.\n10. Females of childbearing potential (females who are not surgically sterile or postmenopausal defined as amenorrhea for \\>12 months) who are not using highly effective contraceptive methods, while on study treatment and for 6 months after last dose of plitidepsin. Fertile males with partners of childbearing potential must use condom during treatment and for 6 months after last dose of plitidepsin. Refer to Annex 2 for contraception requirements.\n11. Unable to consent and\u002For comply with study requirements, in the opinion of the investigator.\n12. Currently participating or participated in a clinical trial within the prior",{"count":144,"type":22},90,[26],"The study aims to prove that plitidepsin could be an efficacious, safe, and well-tolerated therapy for PCC. To this end, we will perform a randomized, double-blind study comparing the clinical and laboratory benefits of plitidepsin vs. placebo in 90 subjects with moderate to severe functional disability. The study consists of an intervention period and a follow-up period, with a total of 135 +\u002F-3 days approximately between both periods.\n\nDuring the intervention period, four treatment cycles will be administered, scheduled every 15 days (every 2 weeks), with intravenous (IV) infusion over three consecutive days. After completing the intervention period, a 90-day (+\u002F-5) follow-up period will be conducted.\n\nSubjects in arm A will receive the plitidepsin 1.5 mg\u002Fday 1h-IV during the four treatment periods on Days 1 to 3, Days 15 to 17, Days 29 to 31 and Days 43 to 45. Subjects in arm B will receive 1h-IV placebo 1 vial \u002Fday during the first two treatment periods and will receive the plitidepsin 1.5 mg\u002Fday 1h-IV during the last two treatment periods. Subjects in arm C will receive 1h-IV placebo 1 vial\u002Fday during the four treatment periods.",[30,148,149,150,29],"Long COVID Syndrome","Persistent COVID-19","Persistent COVID Condition",[152,153,154,155],"SARS-CoV-2","COVID-19","Long COVID19","Plitidepsin","2026-04-02",{"date":158,"type":36},"2026-04-03",{"date":160,"type":36},"2025-02-07",{"date":162,"type":22},"2026-09-01",{"name":164,"class":43},"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia",{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":17,"minAge":116,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":172,"phases":4,"briefSummary":173,"conditions":174,"keywords":180,"overallStatus":188,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":192,"locationsCount":195},"100618493","expanded-access-use-of-human-umbilical-cord-blood-regenecyte-infusion-in-patients-with-chronic-fatigue-of-post-covid-condition-100618493","NCT07332338","Expanded Access Use of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Chronic Fatigue of Post-COVID Condition","Expanded Access Use of Human Umbilical Cord Blood (REGENECYTE) Infusion for Patients With Post-COVID Condition","Inclusion Criteria:\n\n* Male or female aged ≥ 18\n* With post-COVID condition\n* Has had a recent (within 7 days) negative SARS-CoV-2 test (an approved PCR (polyermerase chain reaction) or antigen test)\n* Not eligible for participation in any ongoing clinical trials of post-COVID condition with REGENECYTE\n* Able to provide signed informed consent (by the subject or his\u002Fher legally authorized representative)\n* Is willing and able to participate in all aspects of the study, including completion of subjective evaluations, attendance at scheduled clinic visits, and compliance with all protocol requirements as evidenced by providing a written informed consent\n\nExclusion Criteria:\n\n* Neurological disorders prior to COVID-19 diagnosis\n* With pre-existing terminal illness\n* With known immune disease\n* Is pregnant or breastfeeding\n* Is currently participating in another investigational study or has been taking any other investigational product (IP) within the last 4 weeks before screening\n* Has received any vaccination within 3 weeks prior to the first IP infusion or planning to receive vaccination during the treatment period\n* Judged by the investigator to be not suitable for study participation, including but not limited to pre-existing chronic diseases\n* Under the conditions that may increase risk of complications based on the medical judgment of the investigator and the parameters","EXPANDED_ACCESS","REGENECYTE® (HPC, Cord Blood (Hematopoietic Progenitor Cell, Cord Blood)) for treatment in patients with post-COVID.",[57,175,176,29,177,178,179],"Post-COVID Condition","Post-COVID Syndrome","Chronic Fatigue","Chronic Fatigue Symptoms","Fatigue Post Viral",[29,181,182,183,184,185,186,187],"Post-COVID syndrome","Post-COVID condition","Umbilical cord blood","REGENECYTE","Post-COVID fatigue","Chronic fatigue symptoms","Fatigue post viral","AVAILABLE","2026-03-18",{"date":191,"type":36},"2026-03-23",{"name":193,"class":194},"StemCyte, Inc.","INDUSTRY",2,{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":11,"sex":17,"minAge":116,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":23,"phases":206,"briefSummary":208,"conditions":209,"keywords":213,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":134},"100522430","improving-post-covid-19-syndrome-with-hyperbaric-oxygen-treatments-100522430","NCT06082518","Improving Post COVID-19 Syndrome With Hyperbaric Oxygen Treatments","Improving Post COVID-19 Syndrome With Hyperbaric Oxygen Treatments (PCS-HBOT Study)","PCS-HBOT","Inclusion Criteria:\n\n1. Age ≥ 18 years old\n2. Officially diagnosed with post COVID-19 condition by a healthcare practitioner\n3. At least three months since SARS-CoV-2 infection\n4. Symptoms that persist more than 12 weeks:\n\n   * Chronic fatigue (must include) along with one of the following symptoms:\n   * Difficulty thinking or problem solving ('brain fog')\n   * Stress or anxiety\n\nExclusion Criteria:\n\n1. Contraindications\u002Fmedically unfit to receive hyperbaric treatments at an outpatient facility (pneumothorax, in-patients, requiring infusions to maintain hemodynamics, active and unstable coronary disease)\n2. Patients with cognitive difficulties and\u002For mental retardation before COVID diagnosis\n3. History of traumatic brain injury\n4. Unlikely to comply with follow-up assessments (e.g. no fixed address, plans to move out of town)\n5. Known pregnancy or planning a pregnancy in women of childbearing age",{"count":205,"type":22},40,[207],"NA","Over 500 million people have been infected with COVID-19, and to date, more than 6 million people have died. Many individuals who have recovered from COVID-19 continue to experience symptoms even after they have been \"cured\" of the disease. This condition is known as post COVID-19 condition, which can have serious health consequences. A common symptom among these individuals is chronic fatigue, characterized by persistent tiredness or lack of energy. This study aims to explore a novel treatment for symptoms of post COVID-19 condition, known as hyperbaric oxygen therapy. This approach has shown promise in helping people with post COVID-19 conditions and treating some other causes of fatigue.\n\nHyperbaric oxygen therapy involves placing patients in a small chamber where they receive high oxygen gas levels. However, this treatment is expensive and time-consuming, and it is unclear if this treatment can be effectively assessed in a large-scale research study. This small study will help us decide if conducting a large research study is feasible. The investigators aim to assess if hyperbaric oxygen therapy can improve symptoms of post COVID-19 condition, such as fatigue.",[30,210,176,153,211,212],"Post-COVID-19 Syndrome","Fatigue","Fatigue Syndrome, Chronic",[214,215,30,211,216,153],"Hyperbaric Oxygen Therapy","HBOT","Severe Acute Respiratory Syndrome-CoV-2","2026-03-12",{"date":219,"type":36},"2026-03-16",{"date":221,"type":36},"2024-01-02",{"date":223,"type":22},"2027-05",{"name":225,"class":43},"Sunnybrook Health Sciences Centre",{"id":227,"slug":228,"hasResults":11,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":232,"eligibilityCriteria":233,"healthyVolunteers":11,"sex":17,"minAge":116,"maxAge":4,"enrollmentInfo":234,"targetDuration":4,"studyType":23,"phases":236,"briefSummary":237,"conditions":238,"keywords":4,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":134},"100550824","recovering-from-covid-19-lingering-symptoms-adaptive-integrative-medicine-trial---effect-of-hyperbaric-oxygen-therapy-for-the-treatment-of-post-covid-condition-100550824","NCT06452095","Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine Trial - Effect of Hyperbaric Oxygen Therapy for the Treatment of Post COVID Condition","RECLAIM: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine Trial - Effect of Hyperbaric Oxygen Therapy for the Treatment of Post COVID Condition (RECLAIM-HBOT)","RECLAIM-HBOT","Inclusion Criteria:\n\n1. Age ≥18 years;\n2. Positive COVID-19 test by nasopharyngeal swab RT-PCR (reverse transcription polymerase chain reaction) test, antibody or antigen tests at least 3 months prior to randomization; OR Presumed COVID-19 assessed by the site investigator (no positive COVID-19 test) with acute illness after October 15, 2019.\n3. Patients should be treated with standard of care therapies (as discussed in the study manual) for at least 4 weeks prior to entry into trial.\n4. Lingering COVID-19 symptoms beyond 3 months from onset of acute COVID and symptoms have lasted at least 2 months. The onset of COVID is considered the earliest of two dates: the date of positive test or the date of first symptoms;\n5. Lingering symptoms from COVID-19 present at the time of randomization. \"Lingering symptoms of Long COVID\" must include self-reported cognitive dysfunction symptoms.\n6. Female patients of childbearing potential (as assessed by the overseeing Investigator) who are sexually active must agree to practice true abstinence or use effective methods of contraception while on study treatment. Effective methods of contraception must be discussed and approved by the overseeing Investigator.\n7. Must be able to provide informed consent and both willing and able to comply with study requirements.\n8. A confirmed ability to travel to one of the three sites where HBOT or sham can be administered.\n\nExclusion Criteria:\n\n1. Patients who had mechanical ventilation or extracorporeal membrane oxygen (ECMO) for COVID-19;\n2. Current end-organ failure, organ transplantation, or current hospitalization in acute care hospital;\n3. Contraindications to all of the study interventions;\n4. Co-enrolment in another interventional trial (co-enrolment in an observational study is permitted);\n5. Currently pregnant or breastfeeding.\n6. Pneumothorax\n7. Poorly controlled seizure disorder\n8. Chronic sinusitis\n9. Chronic or acute otitis media\n10. Major ear drum trauma.",{"count":235,"type":22},120,[207],"The RECLAIM study platform will be used to explore whether the use of Hyperbaric Oxygen therapy (HBOT) improves the symptoms of post covid cognitive dysfunction.\n\nHyperbaric oxygen therapy is a well-established medical treatment. HBOT promotes healing by delivering a high concentration of oxygen into the body. This high level of oxygen has a number of known benefits, such as growth of new blood vessels, as well as regulating immune and inflammation responses. It helps protect the brain and other nervous tissue from inflammation. HBOT may also have antiviral effects.\n\nCollectively, it has the potential to target the underlying mechanisms believed to play a critical role in the development of Long COVID.\n\nMany individuals with Long COVID complain of fatigue, brain fog, muscle aches and other symptoms. There is evidence to suggest that these symptoms may be a problem with the blood vessels, resulting in abnormal delivery of oxygen to tissues. Thus, our group is investigating whether HBOT improves post-COVID cognitive dysfunction.",[29,239,57],"Post Acute Sequelae of COVID-19","2026-02-19",{"date":242,"type":36},"2026-02-23",{"date":244,"type":36},"2026-01-01",{"date":246,"type":22},"2029-12-31",{"name":248,"class":43},"University Health Network, Toronto",{"id":250,"slug":251,"hasResults":11,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":255,"eligibilityCriteria":256,"healthyVolunteers":11,"sex":17,"minAge":116,"maxAge":4,"enrollmentInfo":257,"targetDuration":4,"studyType":23,"phases":258,"briefSummary":259,"conditions":260,"keywords":265,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":278,"completionDateStruct":279,"leadSponsor":281,"locationsCount":134},"100601455","effects-of-kneipp-hydrotherapy-in-post-covid-19-patients-100601455","NCT07110714","Effects of Kneipp Hydrotherapy in Post-COVID-19 Patients","Effects of Kneipp Hydrotherapy in Post-COVID-19 Patients: A Randomized Controlled Trial","HydroCoVitalB","Inclusion Criteria:\n\n* Diagnosis of Post-COVID Syndrome (ICD-10 code: U08.9)\n* Barthel-Index \\>80\n* Owning a smartphone to receive digital questionnaires and to use the measurement app for heart rate variability\n* Written informed consent\n\nExclusion Criteria:\n\n* Existing contraindications for Kneipp hydrotherapy like severe cardiovascular diseases (e.g., decompensated heart failure, unstable angina pectoris, acute myocardial infarction), severe venous diseases (e.g., acute deep vein thrombosis of the leg), severe neurological diseases (e.g., uncontrolled epilepsy)\n* Prior regular practice of Kneipp applications",{"count":21,"type":22},[207],"This randomized controlled study evaluates the effects of cold water hydrotherapy in patients with Post-COVID Syndrome. The primary aim is to assess changes in quality of life compared to an usual care setting without hydrotherapy treatment.",[30,261,262,263,264],"Post COVID-19 Condition (PCC)","Post COVID-19","Post COVID-19 Syndrome","Long COVID-19 Syndrome",[266,267,268,269,270,271,272,273,274],"therapy","intervention","hydrotherapy","Kneipp","balneotherapy","quality of life","PCC","long COVID","post COVID-19","2025-12-01",{"date":277,"type":36},"2025-12-02",{"date":275,"type":36},{"date":280,"type":22},"2027-10-31",{"name":282,"class":194},"Eggensberger OHG",{"id":284,"slug":285,"hasResults":11,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":4,"eligibilityCriteria":289,"healthyVolunteers":11,"sex":17,"minAge":116,"maxAge":290,"enrollmentInfo":291,"targetDuration":4,"studyType":23,"phases":293,"briefSummary":295,"conditions":296,"keywords":297,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":4},"100607117","phase-3-a-study-of-human-umbilical-cord-blood-regenecyte-infusion-in-patients-with-post-covid-condition-100607117","NCT07184385","A Study of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Post-COVID Condition","A Multicenter, Double-blind, Randomized, Placebo-controlled, Two-arm Phase III Study to Assess the Efficacy of Human Umbilical Cord Blood (REGENECYTE) Infusion in Reducing Fatigue in Post-COVID Condition","Inclusion Criteria:\n\n* Male or female aged ≥ 18\n* With post-COVID condition\n* Has had a recent (within 7 days) negative SARS-CoV-2 test (an approved PCR or antigen test)\n* Able to provide signed informed consent (by the subject or his\u002Fher legally authorized representative)\n* Is willing and able to participate in all aspects of the study, including completion of subjective evaluations, attendance at scheduled clinic visits, and compliance with all protocol requirements as evidenced by providing a written informed consent\n\nExclusion Criteria:\n\n* Neurological disorders prior to COVID-19 diagnosis\n* With pre-existing terminal illness\n* With known immune disease\n* Is pregnant or breastfeeding\n* Is currently participating in another investigational study or has been taking any other investigational product within the last 4 weeks before screening\n* Has received any vaccination within 3 weeks prior to the first IP infusion or planning to receive vaccination during the treatment period\n* Judged by the investigator to be not suitable for study participation, including but not limited to pre-existing chronic diseases\n* Under the conditions that may increase risk of complications based on the medical judgment of the investigator and the parameters","65 Years",{"count":292,"type":22},60,[294],"PHASE3","REGENECYTE (HPC, Cord Blood) for treatment in patients with post-COVID.",[29,57,176,175],[182,181,29,184,185,183],"2025-09-18",{"date":300,"type":36},"2025-09-23",{"date":302,"type":22},"2026-03-31",{"date":304,"type":22},"2027-09-30",{"name":193,"class":194},{"id":307,"slug":308,"hasResults":11,"nctId":309,"briefTitle":310,"officialTitle":311,"acronym":312,"eligibilityCriteria":313,"healthyVolunteers":11,"sex":17,"minAge":116,"maxAge":4,"enrollmentInfo":314,"targetDuration":4,"studyType":23,"phases":315,"briefSummary":316,"conditions":317,"keywords":4,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":326},"100587447","effect-of-hi-oxsr-for-the-treatment-of-post-covid-condition-100587447","NCT06928506","Effect of Hi-OxSR for the Treatment of Post COVID Condition","RECLAIM: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine Trial - Effect of Hi-OxSR for the Treatment of Post COVID Condition (RECLAIM-HiOxSR)","RECLAIM-HiOxSR","Inclusion Criteria:\n\n1. Age ≥18 years;\n2. Positive COVID-19 test by nasopharyngeal swab RT-PCR (reverse transcription polymerase chain reaction) test, antibody or antigen tests at least 3 months prior to randomization; OR Presumed COVID-19 assessed by the site investigator (no positive COVID-19 test) with acute illness after October 15, 2019.\n3. Patients should be treated with standard of care therapies (as discussed in the study manual) for at least 4 weeks prior to entry into trial.\n4. Lingering COVID-19 symptoms beyond 3 months from onset of acute COVID and symptoms have lasted at least 2 months. The onset of COVID is considered the earliest of two dates: the date of positive test or the date of first symptoms;\n5. Lingering symptoms from COVID-19 present at the time of randomization. \"Lingering symptoms of Long COVID\" must include self-reported cognitive dysfunction symptoms.\n6. Female patients of childbearing potential (as assessed by the overseeing Investigator) who are sexually active must agree to practice true abstinence or use effective methods of contraception while on study treatment. Effective methods of contraception must be discussed and approved by the overseeing Investigator.\n7. Must be able to provide informed consent and both willing and able to comply with study requirements.\n8. Oxygen saturation on room air ≥92% at screening measured by pulse oximeter.\n\nExclusion Criteria:\n\n1. Patients who had mechanical ventilation or extracorporeal membrane oxygen (ECMO) for COVID-19;\n2. Current end-organ failure, organ transplantation, or current hospitalization in acute care hospital;\n3. Contraindications to all of the study interventions;\n4. Co-enrolment in another interventional trial (co-enrolment in an observational study is permitted);\n5. Currently pregnant or breastfeeding.\n6. Known physician diagnosis of cognitive dysfunction prior to COVID infection\n7. Use of an investigational drug\u002Fdevice or other interventions within 30 days of screening\n8. Use of home oxygen (O2) at baseline\n9. History of pulmonary hypertension\n10. Interstitial pulmonary fibrosis\n11. Moderate to severe chronic obstructive pulmonary disease (COPD)\n12. History of narcolepsy\n13. Presence of a condition or abnormality that in the opinion of the investigator would compromise the safety of the participant or the quality of the data.",{"count":235,"type":22},[207],"The RECLAIM study platform will be used to explore whether the use of the Hi-OxSR device improves the symptoms of post covid cognitive dysfunction. Carbon dioxide (CO2) has been proposed as a potential treatment for persistent immune activation as there is evidence that CO2 has antioxidant, anti-inflammatory, and anti-cytokine effects. We conducted a pilot study assessing the open label use of re-breathing CO2 (using Hi-OxSR) twice a day for 14 days, for the treatment of post-COVID cognitive dysfunction. Significant improvements were found in multiple cognitive assessments using TestMyBrain cognitive tests and brain fog (MSNQ) and fatigue scores. This phase 2 clinical trial seeks to build on current findings to determine the optimal effective dose of treatment (i.e. length of use, oxygen concentration, without or without CO2 rebreathing) and the safety of using Hi-OxSR in this patient population.",[29,30,239],"2025-09-11",{"date":320,"type":36},"2025-09-15",{"date":322,"type":36},"2025-08-01",{"date":324,"type":22},"2028-12",{"name":248,"class":43},3,{"id":328,"slug":329,"hasResults":11,"nctId":330,"briefTitle":331,"officialTitle":332,"acronym":4,"eligibilityCriteria":333,"healthyVolunteers":11,"sex":17,"minAge":116,"maxAge":290,"enrollmentInfo":334,"targetDuration":4,"studyType":23,"phases":335,"briefSummary":336,"conditions":337,"keywords":4,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":339,"startDateStruct":341,"completionDateStruct":343,"leadSponsor":345,"locationsCount":134},"100582585","post-covid-19-syndrome-treatment-with-variable-pulse-transcranial-magnetic-stimulation-100582585","NCT06865222","Post COVID-19 Syndrome Treatment With Variable Pulse Transcranial Magnetic Stimulation","Variable Pulse Transcranial Magnetic Stimulation for Treatment of Post COVID Syndrome","Inclusion Criteria:\n\n* Patients who have had a recent episode of COVID-19 and who present to the Post COVID-19 Clinic at Mayo Clinic Rochester with at least one of the PCC symptoms of interest - anosmia, tinnitus, fatigue. Symptoms consistent with PCC lasting at least 1 month after the positive test date. Subjects must have ongoing symptoms for \\> 4 weeks following the start of an acute covid infection. This is consistent with the CDC definition for post covid conditions. Start date is determined by date of first positive COVID test. There is no limitation of maximum time from acute infection start.\n* At least one of the PCC symptoms of interest:\n\n  * Anosmia: Olfactory Threshold Test scores corresponding to Anosmia or Hyposmia\n  * Tinnitus: \\>0 score on Tinnitus Handicap Inventory (not present prior to SARS-COVID 2 infection)\n  * Fatigue: Total Modified Fatigue Impact Scale (MFIS) Score of 40 or above\n\nExclusion Criteria:\n\n* Implanted electronic devices, including pacemakers, defibrillators, implant medication pumps, or vagus nerve stimulators (VNS)\n* Active alcohol abuse: \\>14 drinks a week or formal diagnosis, illicit drug use or drug abuse\n* Any seizure history within the past 10 years\n* Intracranial implant within 30 cm of magnet (e.g., aneurysm clips, endovascular coil, cerebral shunts, brain stimulators, cochlear implants, stents, or electrodes) or any other metal object within or near the head, excluding the mouth, which cannot be safely removed\n* Enrolled or plans to enroll in an interventional trial during this study\n* Previous stroke with residual deficits\n* Subjects unable to comprehend or follow verbal commands\n* Subjects unable to comprehend and sign the informed consent\n* Based on PI's or local physician's assessment that subject unable to tolerate the trial procedure due to medical condition\n* Clinical abnormality or clinically unstable medical condition, as indicated by medical history, physical examination, or clinical laboratory testing, that in the Investigator's judgment might pose a potential safety risk to the subject or limit interpretation of the trial results\n* Pregnant or trying to become pregnant; negative urine pregnancy test at screening will be required for females of childbearing potential\n* Any condition which in the judgment of the investigator would prevent the subject from completion of the study",{"count":205,"type":22},[207],"The purpose of this study is to test if Variable Pulse TMS (Transcranial Magnetic Stimulation) can result in objective improvements in patients with Post COVID Syndrome (PCS).",[30],"2025-08-11",{"date":340,"type":36},"2025-08-14",{"date":342,"type":36},"2025-07-22",{"date":344,"type":22},"2027-04",{"name":346,"class":43},"Mayo Clinic",{"id":348,"slug":349,"hasResults":11,"nctId":350,"briefTitle":351,"officialTitle":351,"acronym":352,"eligibilityCriteria":353,"healthyVolunteers":11,"sex":17,"minAge":116,"maxAge":4,"enrollmentInfo":354,"targetDuration":4,"studyType":23,"phases":355,"briefSummary":356,"conditions":357,"keywords":4,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":361,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":366,"locationsCount":134},"100528085","pursuing-reduction-in-fatigue-after-covid-19-via-exercise-and-rehabilitation-prefacer-a-randomized-feasibility-trial-100528085","NCT06156176","Pursuing Reduction in Fatigue After COVID-19 Via Exercise and Rehabilitation (PREFACER): A Randomized Feasibility Trial","PREFACER","Inclusion Criteria:\n\n* Adults of at least 18 years of age\n* Able to provide informed consent\n* Can speak and understand English\n* Documented history of SARS-CoV-2 infection (positive PCR\u002Fantigen test during acute illness or clinical diagnosis by physician during or after the acute illness)\n* Fatigue symptoms within 3 months of COVID-19 infection, lasting at least 2 months\n* Fatigue symptoms cannot be explained by an alternative diagnosis\n* Fatigue symptoms may be new onset following initial recovery from an acute COVID-19 infection or persist from the initial illness\n* Fatigue symptoms may have an episodic nature, fluctuate or relapse over time\n* Minimal functional capability: able to walk 10-15 minutes and be recovered within 30-60 minutes or without significant post-exertional malaise (PEM)\n* Has applicable technology to access Microsoft Teams and Webex (i.e., computer, laptop, tablet)\n\nExclusion Criteria:\n\n* Active SARS-CoV-2 infection\n* Pre-existing physical, cognitive, and\u002For mental health conditions that make exercise contraindicated, consent unattainable, or that cause symptoms similar to those seen in post COVID-19 (e.g., major neurocognitive disorder, schizophrenia, chronic fatigue syndrome) that could affect data\n* Inability to follow study procedures\n* Pregnant and\u002For breastfeeding\n* Received investigational agents as part of a separate study within 30 days of the screening visit\n* Has any type of metal bodily implant in head or heart (i.e., pins, plates, pacemakers)\n* Current participation in other studies related to COVID-19, exercise, and\u002For fatigue interventions OR participation within 30 days of the screening visit",{"count":292,"type":22},[207],"Long COVID is a complex condition that affects approximately 1.4 million Canadians following SARS-CoV-2 infection. Fatigue is the most common symptom of Long COVID. This feasibility trial will evaluate a new rehabilitation program called COVIDEx for treating fatigue after COVID-19, and compare its effectiveness to the standard treatment currently used. The experimental treatment group will receive an 8-week multi-modal rehabilitation program with two 50-minute sessions per week. 60 participants will be recruited, randomly assigned to the COVIDEx program or standard of care (SoC) and followed for 24 weeks.",[358,359,210,176,211,30,175],"Long-COVID","Long COVID-19","2025-07-29",{"date":322,"type":36},{"date":363,"type":36},"2025-04-01",{"date":365,"type":22},"2026-04-01",{"name":367,"class":43},"Lawson Research Institute of St. Joseph's",{"id":369,"slug":370,"hasResults":11,"nctId":371,"briefTitle":372,"officialTitle":373,"acronym":374,"eligibilityCriteria":375,"healthyVolunteers":115,"sex":17,"minAge":116,"maxAge":376,"enrollmentInfo":377,"targetDuration":4,"studyType":119,"phases":4,"briefSummary":378,"conditions":379,"keywords":383,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":386,"startDateStruct":388,"completionDateStruct":390,"leadSponsor":392,"locationsCount":134},"100505866","ventilatory-and-perfusion-abnormalities-in-individuals-with-post-acute-sequelae-of-sars-cov-2-infection-100505866","NCT05866952","Ventilatory and Perfusion Abnormalities in Individuals With Post-Acute Sequelae of SARS-CoV-2 Infection","Quantitative Computed Tomography to Assess Ventilatory and Perfusion Abnormalities in Individuals With Post-Acute Sequelae of SARS-CoV-2 Infection","PASC VQ","Inclusion Criteria:\n\n* Age ≥ 18\n* Self-reported or documented SARS-CoV-2 infection by RT-PCR or Antigen testing \\> 3 months ago or no previous history of SARS-CoV-2 infection (control group only)\n* Normal or mild abnormalities on baseline Pulmonary Function Tests (PFTs)\n* New or worsening symptoms of chronic fatigue, dyspnea or exercise intolerance after COVID-19 with otherwise unclear etiology (PASC group only)\n\nExclusion Criteria:\n\n* SARS-CoV-2 infection by RT-PCR or Antigen testing within the last 3 months\n* Inability to provide consent or non-English speaking\n* Pregnancy\n* Any respiratory infection in last 4 weeks\n* PFT relative contraindications\n* History of major cardiovascular, pulmonary, renal, hepatic, autoimmune or neuromuscular disease including asthma, COPD, interstitial lung disease, heart failure, pulmonary arterial hypertension, or prior pulmonary embolism\n* Active malignancy undergoing treatment or history of malignancy involving the lung","99 Years",{"count":205,"type":22},"Prospective cohort study to evaluate the utility of quantitative CT analysis to assess ventilation and perfusion defects in patients with Post-acute Sequelae of SARS-CoV-2 (PASC) and functional limitations",[380,30,381,382],"Post-Acute COVID-19","Post Viral Fatigue","Dyspnea",[384],"Ventilation Perfusion Mismatch","2025-07-16",{"date":387,"type":36},"2025-07-20",{"date":389,"type":36},"2023-06-05",{"date":391,"type":22},"2026-12-31",{"name":393,"class":43},"Tufts Medical Center",{"id":395,"slug":396,"hasResults":11,"nctId":397,"briefTitle":398,"officialTitle":399,"acronym":4,"eligibilityCriteria":400,"healthyVolunteers":11,"sex":17,"minAge":116,"maxAge":4,"enrollmentInfo":401,"targetDuration":4,"studyType":23,"phases":402,"briefSummary":403,"conditions":404,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":405,"lastUpdatePostDateStruct":406,"startDateStruct":408,"completionDateStruct":410,"leadSponsor":412,"locationsCount":134},"100568284","improving-health-status-in-covid-19-long-hauler-100568284","NCT06679218","Improving Health Status in COVID-19 Long-Hauler","Improving Health Status in COVID-19 Long-Hauler Through an Activity Coaching Programme: a Randomized Control Trial","Inclusion Criteria:\n\n* Patients of both sexes.\n* Agreed to participate.\n* Post COVID-19 condition patients meeting the WHO definition for this disease.\n* Sedentary patients according to the cut-off point of the International Physical Activity Questionnaire (IPAQ).\n\nExclusion Criteria:\n\n* Pulmonary, cardiac, neurological, vascular, or orthopaedic pathologies that could limit the execution of the evaluation and intervention.\n* Cognitive impairment that prevented them from understanding and answering the questionnaires.\n* Patients suffering from a reinfection with SARS-CoV-2.\n* Patients with a history of severe or critical COVID-19 disease severity.\n* Patients participating in other studies.",{"count":292,"type":22},[207],"This randomized clinical trial investigates the effects of a distance physical activity coaching program on the health of COVID-19 long-hauler. The study evaluates the impact of individualized coaching interventions to improve participants' physical activity and quality of life.",[30],"2024-11-06",{"date":407,"type":36},"2024-11-07",{"date":409,"type":22},"2024-11-11",{"date":411,"type":22},"2025-01-20",{"name":413,"class":43},"Universidad de Granada",{"id":415,"slug":416,"hasResults":11,"nctId":417,"briefTitle":418,"officialTitle":419,"acronym":420,"eligibilityCriteria":421,"healthyVolunteers":11,"sex":17,"minAge":116,"maxAge":4,"enrollmentInfo":422,"targetDuration":4,"studyType":23,"phases":424,"briefSummary":425,"conditions":426,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":428,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":434,"locationsCount":4},"100559907","evaluation-of-the-effectiveness-of-a-spa-treatment-for-people-with-post-covid-19-conditions-100559907","NCT06570239","Evaluation of the Effectiveness of a Spa Treatment for People With Post-Covid 19 Conditions.","Efficacy of Spa Management (Hydrokinesitherapy and Crenobalneotherapy) Compared With Usual Management of People With Post-Covid-19 Conditions: a Randomized, Open-label Clinical Trial.","COVIDTHERM","Inclusion Criteria:\n\n* Person who has received full information about the organisation of the research, who has not\n* to their participation and the use of their data, and who have given their free and free and informed consent in writing,\n* Patients aged 18 and over,\n* Patients with a history of symptomatic Covid-19 infection documented by RTPCR, antigenic test, positive serology in a patient not previously vaccinated or other virological diagnostic test validated at the patient's inclusion date,\n* A person who has not required hospitalisation for treatment in the initial phase of Covid-19,\n* Person presenting at least two common symptoms of the post-Covid condition from among fatigue, breathlessness, cognitive dysfunction, appearing de novo and evolving for more than for more than 12 weeks and present for more than 8 weeks,\n* Initial and prolonged symptoms not explained by another diagnosis with no known link to with Covid-19,\n* Normal SpO2 at rest not decreasing beyond 4% on exercise,\n* Membership of a social security scheme or beneficiary of such a scheme.\n\nExclusion Criteria:\n\n* Acute cardiovascular disease (acute coronary syndrome, arrhythmia, heart failure, venous thromboembolism venous thromboembolic disease, myocarditis, stroke, acute ischaemia, etc.) less than stroke, acute ischaemia, etc.) less than 3 months old and at risk of recurrence or decompensation,\n* Respiratory disease: COPD, interstitial fibrosis, exercise-induced desaturation, sleep apnoea\n* Stroke less than 6 months old,\n* Pregnant women,\n* Adults subject to a legal protection measure (guardianship, curatorship, safeguard of justice),\n* Serious and unstable psychiatric pathology, severe depressive syndrome, delirious decompensation, panic attacks, anxiety-depression syndrome,\n* Acute and progressive conditions (infectious, cancerous and inflammatory),\n* Person with a contraindication to hydrokinesitherapy and crenotherapy crenotherapy (infected dermatoses, severe immune deficiencies, inflammatory diseases, faecal or urinary incontinence, presence of a suprapubic or intravenous catheter, colostomy, hydrophobia)\n* Refusal to sign the free and informed consent form",{"count":423,"type":22},200,[207],"Following the acute phase of Covid-19, some patients experience persistent or recurrent symptoms. These symptoms can take a number of forms: intense fatigue, cognitive dysfunction, respiratory difficulties, maladaptation to physical exertion, musculoskeletal pain, anxiety-depressive disorders, malnutrition, loss of sense of smell, headaches and so on. These symptoms are known as post-covid-19 disease, defined by the WHO as \"a condition occurring in people with a history of probable or confirmed infection with SARS-CoV-2, usually 3 months after the onset of COVID-19 with symptoms that persist for at least 2 months and cannot be explained by another diagnosis. Common symptoms include fatigue, breathlessness and cognitive dysfunction, as well as other symptoms that generally have an impact on daily functioning.\n\nThe aim of this interventional research project is to assess the place of a specific spa treatment for people with a post-Covid 19 condition in the primary care pathway.",[30],"2024-08-22",{"date":429,"type":36},"2024-08-26",{"date":431,"type":22},"2024-10-01",{"date":433,"type":22},"2026-10-01",{"name":435,"class":43},"Central Hospital, Nancy, France",{"id":437,"slug":438,"hasResults":11,"nctId":439,"briefTitle":440,"officialTitle":441,"acronym":442,"eligibilityCriteria":443,"healthyVolunteers":115,"sex":17,"minAge":116,"maxAge":444,"enrollmentInfo":445,"targetDuration":4,"studyType":23,"phases":447,"briefSummary":448,"conditions":449,"keywords":451,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":455,"lastUpdatePostDateStruct":456,"startDateStruct":458,"completionDateStruct":460,"leadSponsor":462,"locationsCount":134},"100511981","mr-spectroscopy-in-post-covid-condition-prior-to-and-following-a-yoga-breathing-intervention-100511981","NCT05946512","MR-spectroscopy in Post-covid Condition Prior to and Following a Yoga Breathing Intervention","MR Spectroscopy in Well-characterized Individuals With and Without Post COVID Condition Prior to and Following a Yoga Breathing Intervention- an Explorative Randomised Controlled Trial","SpeCY","Inclusion Criteria:\n\n* Inclusion criteria for participants with Post COVID condition\n\n  1. Eligible patients will be recruited at the Respiratory Outpatient Clinic (Medical University Innsbruck, Internal Medicine II) from the PRECISE registry or from other participating clinics at Medical University Innsbruck and via local advertisement.\n  2. Persistent respiratory symptoms for 3 months after infection (mMRC dyspnea score ≥ 1).\n  3. Absence of obstructive or restrictive lung disease or unilateral diaphragmatic paresis.\n  4. Medical history with symptoms compatible with DB as assessed by the physician AND Nijmegen cut-off score of \\>23 or reduced MIP. The last two conditions were chosen to provide a readily accessible and objectifiable entry criterion at the inclusion visit.\n  5. Age \\>= 18 years, \\\u003C 50 years.\n  6. Sufficient knowledge of German language for interaction during Yoga and completion of questionnaires.\n\nInclusion criteria for participants with COPD\n\n1. Eligible patients will be recruited at the Respiratory Outpatient Clinic (Medical University Innsbruck).\n2. A postbronchodilator FEV1\u002FFVC ratio less than 0,7 obtained in functional pulmonary testing is required fo diagnosis of COPD (Global Initiative for Chronic Obstructive Lung Disease (GOLD) Science Committee, 2022).\n3. Persistent respiratory symptoms for 3 months (mMRC≥ 1).\n4. Absence of unilateral diaphragmatic paresis.\n5. Medical history with symptoms compatible with DB as assessed by the physician AND Nijmegen cut-off score of \\>23 or reduced MIP. The last two conditions were chosen to provide a readily accessible and objectifiable entry criterion at the inclusion visit.\n6. Age \\>= 18 years, \\\u003C 50 years\n7. Sufficient knowledge of German language for interaction during Yoga and completion of questionnaires\n\nInclusion criteria for participants with somatic symptom disorder\n\n1. Eligible patients will be recruited at University Hospital for Psychiatry I and II, Medical University Innsbruck) and via local advertisement.\n2. Screening positive for somatic symptoms disorder with the following scores: SSD-12 ≥ 23, SSS-8 ≥ 9.\n3. Persistent respiratory symptoms for 3 months after infection (mMRC≥ 1).\n4. Absence of obstructive or restrictive lung disease or unilateral diaphragmatic paresis.\n5. Absence of medical history with symptoms compatible with DB as assessed by the physician AND Nijmegen cut-off score of \\>23 or reduced MIP. The last two conditions were chosen to provide a readily accessible and objectifiable entry criterion at the inclusion visit.\n6. Age \\>= 18 years, \\\u003C 50 years.\n7. Sufficient knowledge of German language for interaction during Yoga and completion of questionnaires.\n\nInclusion criteria for healthy participants\n\n1. Eligible participants will be recruited via local advertisement.\n2. Absence of significant active mental or somatic disorders\n3. Absence of persistent respiratory symptoms (mMRC\\\u003C 1).\n4. Absence of obstructive or restrictive lung disease or unilateral diaphragmatic paresis.\n5. Absence of medical history with symptoms compatible with DB as assessed by the physician AND Nijmegen questionnaire and MIP within normal limits..\n6. Age \\>= 18 years, \\\u003C 50 years.\n7. Sufficient knowledge of German language for interaction during Yoga and completion of questionnaires.\n\nExclusion Criteria:\n\n* Exclusion criteria for participants with post COVID condition\n\n  1. Conditions precluding magnetic resonance imaging (MRI) such as metal implants in the body (e.g., pacemakers, surgical devices), phobic anxiety, claustrophobia, or pregnancy.\n  2. Active psychiatric conditions interfering with study participation such as psychosis or acute suicidality.\n  3. Severe fatigue interfering with study participation.\n  4. Previous evidence of structural brain abnormality on the structural MRI scan.\n  5. Significant previous meditation or Yoga experience.\n  6. Patients with known carotid stenosis \\>70% or cardiopulmonary contraindications for tilt table and other cardiovascular autonomic function tests (e.g. Valsalva maneuver, deep breathing, standing test).\n\nExclusion criteria for participants with COPD\n\n1. Conditions precluding magnetic resonance imaging (MRI) such as metal implants in the body (e.g., pacemakers, surgical devices), phobic anxiety, claustrophobia, or pregnancy.\n2. Active psychiatric conditions interfering with study participation such as psychosis or acute suicidality.\n3. Severe fatigue interfering with study participation.\n4. Previous evidence of structural brain abnormality on the structural MRI scan.\n5. Medical history of post COVID condition.\n6. Significant previous meditation or Yoga experience.\n7. Patients with known carotid stenosis \\>70% or cardiopulmonary contraindications for tilt table and other cardiovascular autonomic function tests (e.g. Valsalva maneuver, deep breathing, standing test).\n8. Patients dependent on a long-term oxygen therapy (LTOT )\n\nExclusion criteria for participants with somatic symptom disorder\n\n1. Conditions precluding magnetic resonance imaging (MRI) such as metal implants in the body (e.g., pacemakers, surgical devices), phobic anxiety, claustrophobia, or pregnancy.\n2. Other active psychiatric conditions interfering with study participation such as psychosis or acute suicidality.\n3. Severe fatigue interfering with study participation.\n4. Previous evidence of structural brain abnormality on the structural MRI scan.\n5. Medical history of post COVID condition.\n6. Significant previous meditation or Yoga experience.\n7. Patients with known carotid stenosis \\>70% or cardiopulmonary contraindications for tilt table and other cardiovascular autonomic function tests (e.g. Valsalva maneuver, deep breathing, standing test).\n\nExclusion criteria for healthy participants\n\n1. Conditions precluding magnetic resonance imaging (MRI) such as metal implants in the body (e.g., pacemakers, surgical devices), phobic anxiety, claustrophobia, or pregnancy.\n2. Active psychiatric conditions interfering with study participation such as psychosis or acute suicidality.\n3. Previous evidence of structural brain abnormality on the structural MRI scan.\n4. Medical history of post COVID condition.\n5. Significant previous meditation or Yoga experience.\n6. Patients with known carotid stenosis \\>70% or cardiopulmonary contraindications for tilt table and other cardiovascular autonomic function tests (e.g. Valsalva maneuver, deep breathing, standing test).\n\nlegend: PRECISE = a study conducted with participants with post-COVID-19 condition at the Medical University of Innsbruck; mMRC score = modified medical research council score; DB = dysfunctional breathing; MIP = maximal inspiratory pressure; COPD = chronic obstructive pulmonary disease; FEV1\u002FFVC = forced expiratory volume in one second\u002F forced vital capacity; SSD-12 = Somatic Symptom Disorder - B Criteria Scale; SSS-8 = Somatic Symptom Scale - 8;","50 Years",{"count":446,"type":22},320,[207],"From a clinical perspective, we find that many patients with Post COVID condition suffer from severe and debilitating shortness of breath, while routine pulmonary investigations fail to find the cause of the problems experienced. If dyspnea is associated with palpitations, dizziness or anxiety, patients are commonly diagnosed with \"dysfunctional breathing\". From a psychosomatic perspective, the symptom of dysfunctional breathing can be classified as a \"functional symptom\" under the umbrella term of somatic symptom disorder. Therefore, Yoga interventions with special emphasis on breath-guided relaxation are a promising approach. We aim to investigate the psycho-somatic and somato-psychic pathophysiology on a morphological, psychological, functional and biological basis underlying the symptom of dysfunctional breathing. Furthermore, we plan to investigate the mechanism of Yoga intervention on the mental and somatic symptom burden of participants with Post COVID condition. Then, we aim to compare the impact of Yoga on other groups - healthy individuals, patients with chronic obstructive lung disease (COPD), as well as those with somatic symptom disorder. As a control intervention to Yoga guided breathing exercises a social contact group will be used.",[30,450],"Somatic Symptom Disorder",[452,453,454],"Yoga breathing intervention","dysfunctional breathing","MR-Spectroscopy","2023-07-13",{"date":457,"type":36},"2023-07-14",{"date":459,"type":22},"2023-07-24",{"date":461,"type":22},"2027-01-01",{"name":463,"class":43},"Medical University Innsbruck"]